This is a prospective study designed to evaluate the structural and functional integrity of transcatheter or surgical bioprosthetic valves with multimodality imaging. The study further aims to confirm resolution of the early bioprosthetic valve thrombotic changes with anticoagulation.
Presence of transcatheter or surgical bioprosthetic aortic valve implanted at least 48 hours prior to enrollment
Age 18 years or older
Ability to provide informed consent and follow-up with protocol procedures.
Renal insufficiency (creatinine > 1.5 mg/dL)
Known allergy to iodinated contrast agents
Single group
Warfarin
DrugPatients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
Frequency of patients with structural/functional abnormalities of bioprosthetic valves
Percentage of patients with resolution of bioprosthetic valve thrombotic lesions with anticoagulation
Click on the lead sponsor to view all of their trials.
